Literature DB >> 17565561

Methamphetamine and cardiovascular pathology: a review of the evidence.

Sharlene Kaye1, Rebecca McKetin, Johan Duflou, Shane Darke.   

Abstract

AIMS: To examine the literature pertaining to the cardiovascular effects of methamphetamine and discuss the implications for methamphetamine users.
METHODS: Relevant literature was identified through comprehensive MEDLINE and EMBASE searches. FINDINGS AND
CONCLUSIONS: There is sufficient clinical and experimental evidence to suggest that methamphetamine can have adverse and potentially fatal effects on the cardiovascular system. The existing literature suggests that: (1) methamphetamine users are at elevated risk of cardiac pathology; (2) risk is not likely to be limited to the duration of their methamphetamine use, because of the chronic pathology associated with methamphetamine use; (3) the risk of cardiac pathology is greatest among chronic methamphetamine users; (4) pre-existing cardiac pathology, due to methamphetamine use or other factors, increases the risk of an acute cardiac event; and (5) methamphetamine use is likely to exacerbate the risk of cardiac pathology from other causes, and may therefore lead to premature mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565561     DOI: 10.1111/j.1360-0443.2007.01874.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  74 in total

1.  Aortic dissection in young adults who abuse amphetamines.

Authors:  Arthur N Westover; Paul A Nakonezny
Journal:  Am Heart J       Date:  2010-08       Impact factor: 4.749

2.  Methamphetamine craving induced in an online virtual reality environment.

Authors:  Christopher Culbertson; Sam Nicolas; Itay Zaharovits; Edythe D London; Richard De La Garza; Arthur L Brody; Thomas F Newton
Journal:  Pharmacol Biochem Behav       Date:  2010-07-17       Impact factor: 3.533

3.  Effect of methamphetamine dependence on heart rate variability.

Authors:  Brook L Henry; Arpi Minassian; William Perry
Journal:  Addict Biol       Date:  2010-12-23       Impact factor: 4.280

4.  Racial disparities in methamphetamine-associated intracerebral hemorrhage.

Authors:  Kazuma Nakagawa; Megan A Vento; Marissa M Ing; Todd B Seto
Journal:  Neurology       Date:  2015-02-06       Impact factor: 9.910

5.  Longitudinal changes in drug use severity and physical health-related quality of life among untreated stimulant users.

Authors:  Tyrone F Borders; Brenda M Booth; Russel S Falck; Carl Leukefeld; Jichuan Wang; Robert G Carlson
Journal:  Addict Behav       Date:  2009-06-06       Impact factor: 3.913

6.  Mobile thoracic aortic thrombus in a methamphetamine user after cardiac arrest.

Authors:  Venkata M Alla; Ramya Thota; Shawn Mathias; Mark Holmberg; Claire Hunter
Journal:  Tex Heart Inst J       Date:  2011

7.  Symptomatic Exposures Among California Inmates 2011-2013.

Authors:  Michael Butterfield; Suad Al-Abri; Serena Huntington; Terry Carlson; Richard J Geller; Kent R Olson
Journal:  J Med Toxicol       Date:  2015-09

8.  Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.

Authors:  Ana B Sanchez; Giuseppe P Varano; Cyrus M de Rozieres; Ricky Maung; Irene C Catalan; Cari C Dowling; Natalia E Sejbuk; Melanie M Hoefer; Marcus Kaul
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

9.  Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Authors:  Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison
Journal:  Addiction       Date:  2014-03-17       Impact factor: 6.526

10.  Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Elena Shumay; Frank Telang; Peter K Thanos; David Alexoff
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.